Search
Human vaccinia virus immune globulin
go.drugbank.com/drugs/DB14112ApprovedInvestigationalNevertheless, VIG by virtue of the way it is produced is a poorly characterized and highly variable human product that is only available in very limited quantities - all factors that may intervene with
Categories: Immunoglobulin G, Human Immunoglobulin GIMCY-0141
go.drugbank.com/drugs/DB17019InvestigationalIMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin
Tafenoquine
go.drugbank.com/drugs/DB06608ApprovedInvestigational[A35677] It was FDA approved on July 20, 2018.[L3770] … Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group.
Ciltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigationala range of symptoms including bone pain, hematologic abnormalities, and end-organ damage. … [A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development
Lumiliximab
go.drugbank.com/drugs/DB06162InvestigationalClinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints. … Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.
Synonyms: IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER, IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMERSuzetrigine
go.drugbank.com/drugs/DB18927ApprovedInvestigational[A264953] On January 30, 2025, suzetrigine was approved by the FDA as a first-in-class non-opioid analgesic.[L52098] … Suzetrigine is a Na<sub>V</sub>1.8 voltage-gated sodium channel blocker with analgesic properties[A264948] Na<sub>V</sub>1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain
Aminoglutethimide
go.drugbank.com/drugs/DB00357ApprovedWithdrawn(From Martindale, The Extra Pharmacopoeia, 30th ed, p454) … Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties.
Synonyms: DL-AminoglutethimideSonrotoclax
go.drugbank.com/drugs/DB18753ApprovedInvestigationalSonrotoclax is a selective, potent, small-molecule inhibitor of BCL-2, an antiapoptotic protein overexpressed in B-cell malignancies. … [L56193,L56194] The application received priority review, breakthrough therapy designation, and orphan drug designation, and was reviewed under Project Orbis with the EMA as an official observer.
Synonyms: N-[4-({[(1r,4r)-4-hydroxy-4-methylcyclohexyl]methyl}amino)-3- nitrobenzene-1-sulfonyl]-4-(2-{(2S)-2-[2-(propan-2-yl)phenyl]pyrrolidin- 1-yl}-7-azaspiro[3.5]nonan-7-yl)-2-[(1H-pyrrolo[2,3-b]pyridin-5- ylSotrovimab
go.drugbank.com/drugs/DB16355ApprovedInvestigational[L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective. … found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting.
Bufexamac
go.drugbank.com/drugs/DB13346ApprovedWithdrawnBufexamac was also withdrawn by the EMA in April 2010. … The use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization [A32822].
Synonyms: 4-Butoxy-N-hydroxybenzeneacetamide